Growth in Infants and Children With Intestinal Failure-associated Liver Disease Treated With Intravenous Fish Oil.
Journal
Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
entrez:
25
1
2020
pubmed:
25
1
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
Infants with intestinal failure (IF) and IF-associated liver disease (IFALD) are at risk for poor somatic growth because of increased metabolic demands, inadequate intake, intestinal malabsorption, chronic liver disease and other comorbidities. There are limited data on the nutritional adequacy of intravenous fish oil lipid emulsion (FOLE) compared with standard soybean oil lipid emulsion (SOLE) in the setting of intestinal failure. To describe growth patterns in a large cohort of infants with IFALD treated with FOLE. We compared growth data from infants enrolled in a single-center, prospective FOLE study to published norms, as well as to a multicenter, historical cohort of infants with IF treated with SOLE. One hundred thirty-eight infants with IFALD were treated with FOLE and 108 with SOLE. Compared with normative growth curves from WHO and published preterm data, infants in both groups from 6 to 11 months postmenstrual age exhibited declines in mean weight- and length-for-age z scores. At 24 months postmenstrual age compared with WHO growth data, infants treated with FOLE had a mean (95% confidence interval [CI]) weight-for-age z-score of 0.13 (-0.18 to 0.45) and length-for-age z-score of 0.07 (-0.33 to 0.47). In comparison, at 24 months postmenstrual age, infants treated with SOLE had a mean weight for age z-score of -0.93 (-1.20 to -0.67) and mean length for age z-score of -2.33 (-2.75 to -1.91). Independent predictors of higher weight, length and head circumference z-scores included older postmenstrual age at baseline, fewer central line-associated blood stream infections, resolution of cholestasis, type of intravenous fat emulsion (FOLE vs SOLE) and female sex. Infants with IFALD treated with FOLE showed comparable somatic growth to those treated with SOLE in early infancy, and improved somatic growth up to 24 months of age, supporting its wider use in this patient population.
Sections du résumé
BACKGROUND
Infants with intestinal failure (IF) and IF-associated liver disease (IFALD) are at risk for poor somatic growth because of increased metabolic demands, inadequate intake, intestinal malabsorption, chronic liver disease and other comorbidities. There are limited data on the nutritional adequacy of intravenous fish oil lipid emulsion (FOLE) compared with standard soybean oil lipid emulsion (SOLE) in the setting of intestinal failure.
AIMS
To describe growth patterns in a large cohort of infants with IFALD treated with FOLE.
METHODS
We compared growth data from infants enrolled in a single-center, prospective FOLE study to published norms, as well as to a multicenter, historical cohort of infants with IF treated with SOLE.
RESULTS
One hundred thirty-eight infants with IFALD were treated with FOLE and 108 with SOLE. Compared with normative growth curves from WHO and published preterm data, infants in both groups from 6 to 11 months postmenstrual age exhibited declines in mean weight- and length-for-age z scores. At 24 months postmenstrual age compared with WHO growth data, infants treated with FOLE had a mean (95% confidence interval [CI]) weight-for-age z-score of 0.13 (-0.18 to 0.45) and length-for-age z-score of 0.07 (-0.33 to 0.47). In comparison, at 24 months postmenstrual age, infants treated with SOLE had a mean weight for age z-score of -0.93 (-1.20 to -0.67) and mean length for age z-score of -2.33 (-2.75 to -1.91). Independent predictors of higher weight, length and head circumference z-scores included older postmenstrual age at baseline, fewer central line-associated blood stream infections, resolution of cholestasis, type of intravenous fat emulsion (FOLE vs SOLE) and female sex.
CONCLUSIONS
Infants with IFALD treated with FOLE showed comparable somatic growth to those treated with SOLE in early infancy, and improved somatic growth up to 24 months of age, supporting its wider use in this patient population.
Identifiants
pubmed: 31978030
doi: 10.1097/MPG.0000000000002551
pii: 00005176-202002000-00026
doi:
Substances chimiques
Fat Emulsions, Intravenous
0
Fish Oils
0
Soybean Oil
8001-22-7
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
261-268Subventions
Organisme : NIDDK NIH HHS
ID : K24 DK104676
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK040561
Pays : United States
Organisme : FDA HHS
ID : R01 FD003436
Pays : United States
Références
Goulet O, Ruemmele F, Lacaille F, et al. Irreversible intestinal failure. J Pediatr Gastroenterol Nutr 2004; 38:250–269.
Duggan CP, Jaksic T. Pediatric intestinal failure. N Engl J Med 2017; 377:666–675.
Koletzko B, Goulet O, Hunt J, et al. Parenteral Nutrition Guidelines Working Group; European Society for Clinical Nutrition and Metabolism; European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN); European Society of Paediatric Research (ESPR). 1. Guidelines on Paediatric Parenteral Nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), Supported by the European Society of Paediatric Research (ESPR). J Pediatr Gastroenterol Nutr 2005; 41: (Suppl 2): S1–S87.
Raphael BP, Duggan C. Prevention and treatment of intestinal failure-associated liver disease in children. Semin Liver Dis 2012; 32:341–347.
Shores DR, Alaish SM, Aucott SW, et al. Postoperative enteral nutrition guidelines reduce the risk of intestinal failure-associated liver disease in surgical infants. J Pediatr 2018; 195:140.e1–147.e1.
Kurvinen A, Nissinen MJ, Andersson S, et al. Parenteral plant sterols and intestinal failure-associated liver disease in neonates. J Pediatr Gastroenterol Nutr 2012; 54:803–811.
Llop JM, Virgili N, Moreno-Villares JM, et al. Phytosterolemia in parenteral nutrition patients: implications for liver disease development. Nutrition 2008; 24:1145–1152.
Carter BA, Taylor OA, Prendergast DR, et al. Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR. Pediatr Res 2007; 62:301–306.
Tazuke Y, Teitelbaum DH. Alteration of canalicular transporters in a mouse model of total parenteral nutrition. J Pediatr Gastroenterol Nutr 2009; 48:193–202.
Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362:1675–1685.
Premkumar MH, Carter BA, Hawthorne KM, et al. High rates of resolution of cholestasis in parenteral nutrition-associated liver disease with fish oil-based lipid emulsion monotherapy. J Pediatr 2013; 162:793.e1–798.e1.
Ekema G, Falchetti D, Boroni G, et al. Reversal of severe parenteral nutrition-associated liver disease in an infant with short bowel syndrome using parenteral fish oil (omega-3 fatty acids). J Pediatr Surgery 2008; 43:1191–1195.
Gura KM, Lee S, Valim C, et al. Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics 2008; 121:e678–e686.
Grimminger F, Wahn H, Mayer K, et al. Impact of arachidonic versus eicosapentaenoic acid on exotonin-induced lung vascular leakage: relation to 4-series versus 5-series leukotriene generation. Am J Respir Crit Care Med 1997; 155:513–519.
Mercer DF. Fish oil emulsions in the management of intestinal failure-associated liver disease. J Clin Gastroenterol 2012; 46:823–827.
El Kasmi KC, Anderson AL, Devereaux MW, et al. Phytosterols promote liver injury and Kupffer cell activation in parenteral nutrition-associated liver disease. Sci Transl Med 2013; 5:206ra137.
Rollins MD, Ward RM, Jackson WD, et al. Effect of decreased parenteral soybean lipid emulsion on hepatic function in infants at risk for parenteral nutrition-associated liver disease: a pilot study. J Pediatr Surg 2013; 48:1348–1356.
Lam G, Strogach IG, Baron N, et al. Normal growth and essential fatty acid status in children with intestinal failure on lipid limitation. J Pediatr Gastroenterol Nutr 2016; 62:335–340.
Puder M, Valim C, Meisel JA, et al. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg 2009; 250:395–402.
Fenton TR, Nasser R, Eliasziw M, et al. Validating the weight gain of preterm infants between the reference growth curve of the fetus and the term infant. BMC Pediatr 2013; 13:92.
Grummer-Strawn LM, Reinold C, Krebs NF. Centers for Disease Control and Prevention (CDC). Use of World Health Organization and CDC growth charts for children aged 0–59 months in the United States. MMWR Recomm Rep 2010; 59 (RR-9):1–15.
Squires RH, Duggan C, Teitelbaum DH, et al. Pediatric Intestinal Failure Consortium. Natural history of pediatric intestinal failure: initial report from the Pediatric Intestinal Failure Consortium. J Pediatr 2012; 161:723.e2–728.e2.
Brown K, Lopez de Romaña G, Graham G, et al. Experience with a mixture of wheat-noodles and casein in the initial dietary therapy of infants and young children with protein-energy malnutrition and acute diarrhea. Hum Nutr Appl Nutr 1982; 36A:354–366.
Rosenbaum PR. Model-based direct adjustment. Journal of the American Statistician 1987; 82:387–394.
Firth D. Bias reduction of maximum likelihood estimates. Biometrika 1993; 90:27–38.
Ruppert D, Wand MP, Carroll RJ. Semiparametric Regression. Cambridge Series in Statistical and Probabilistic Mathematics. 2003; Cambridge; New York: Cambridge University Press, 161–193.
WHO child growth standards SAS macro In: WHO, editor. version 3.2.2 ed. Geneva. https://www.who.int/childgrowth/software/en/. Accessed November 8, 2019.
Akaike H. A new look at the statistical model identification. IEEE Transact Automatic Control 1974; AC-19:716–23.
Brenn M, Gura K, Duggan C. Sonneville K, Duggan C. Intestinal failure. Manual of Pediatric Nutrition 5th ed.Shelton, CT: PMPH-USA; 2014. 424–444.
Gosselin KB, Duggan C. Enteral nutrition in the management of pediatric intestinal failure. J Pediatr 2014; 165:1085–1090.
Cober MP, Killu G, Brattain A, et al. Intravenous fat emulsions reduction for patients with parenteral nutrition-associated liver disease. J Pediatr 2012; 160:421–427.
de Meijer VE, Le HD, Meisel JA, et al. Parenteral fish oil as monotherapy prevents essential fatty acid deficiency in parenteral nutrition-dependent patients. J Pediatr Gastroenterol Nutr 2010; 50:212–218.
Nandivada P, Fell GL, Mitchell PD, et al. Long-term fish oil lipid emulsion use in children with intestinal failure-associated liver disease [formula: see text]. JPEN J Parenter Enteral Nutr 2017; 41:930–937.
Biagetti C, Correani A, D’Ascenzo R, et al. Does intravenous fish oil affect the growth of extremely low birth weight preterm infants on parenteral nutrition? Clin Nutr 2018; 16:32480–32484.
Papandreou P, Agakidis C, Scouroliakou M, et al. Early postnatal changes of bone turnover biomarkers in very low-birth-weight neonates-the effect of two parenteral lipid emulsions with different polyunsaturated fatty acid content: a randomized double-blind study. JPEN J Parenter Enteral Nutr 2019; doi: 10.1002/jpen.1533. [Epub ahead of print].
doi: 10.1002/jpen.1533.
Brenna JT, Salem N Jr, Sinclair AJ, et al. International Society for the Study of Fatty A, Lipids I. alpha-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot Essent Fatty Acids 2009; 80:85–91.
Hintz SR, Kendrick DE, Stoll BJ, et al. Neurodevelopmental and growth outcomes of extremely low birth weight infants after necrotizing enterocolitis. Pediatrics 2005; 115:696–703.
Raphael BP, Mitchell PD, Finkton D, et al. Necrotizing enterocolitis and central line associated blood stream infection are predictors of growth outcomes in infants with short bowel syndrome. J Pediatr 2015; 167:35.e1–40.e1.
McLaughlin CM, Channabasappa N, Pace J, et al. Growth trajectory in children with short bowel syndrome during the first 2 years of life. J Pediatr Gastroenterol Nutr 2018; 66:484–488.
Kaufman SS, Loseke CA, Lupo JV, et al. Influence of bacterial overgrowth and intestinal inflammation on duration of parenteral nutrition in children with short bowel syndrome. J Pediatr 1997; 131:356–361.
Ley D, Duhamel A, Behal H, et al. Growth pattern in paediatric Crohn disease is related to inflammatory status. J Pediatr Gastroenterol Nutr 2016; 63:637–643.
Syed S, Ali A, Duggan C. Environmental enteric dysfunction in children: a review. J Pediatr Gastroenterol Nutr 2016; 63:6–14.
Olieman JF, Penning C, Spoel M, et al. Long-term impact of infantile short bowel syndrome on nutritional status and growth. Br J Nutr 2012; 107:1489–1497.
Olieman JF, Tibboel D, Penning C. Growth and nutritional aspects of infantile short bowel syndrome for the past 2 decades. J Pediatr Surg 2008; 43:2061–2069.